Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients

Anxiety Clinical Trial

Official title:

Vandral Retard (Venlafaxine Extended Release) in Depressive Syndrome With Anxiety and Painful Symptoms in Elderly Patients. Observational Study in Primary Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00247429
• Other study ID #: 101356
• Status: Completed
• Phase: Phase 4
• First received: October 28, 2005
• Last updated: August 31, 2009
• Start date: July 2004
• Est. completion date: October 2005

Study information

• Verified date: August 2009
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Ministry of Health
• Study type: Observational

Clinical Trial Summary

In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome. We will also study secondarily its effects on anxiety, somatic and painful symptoms of depression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: October 2005
• Est. primary completion date: October 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Patients older than 60 years

• Depressive syndrome with associated anxiety symptoms, according to a symptoms intensity HAM-D17³14

Exclusion Criteria:

• Participation in other studies in the last 3 months before the start of the study

• Known hypersensibility to venlafaxine

• Clinically significant abnormalities according to the venlafaxine labeling

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Anxiety
• Depressive Disorder
• Depressive Syndrome

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer